Cargando…
Clinical impact of high platelet reactivity in patients with atrial fibrillation and concomitant percutaneous coronary intervention on dual or triple antithrombotic therapy
High platelet reactivity (HPR) on clopidogrel is an established thrombotic risk factor after percutaneous coronary intervention (PCI). The introduction of more potent antiplatelet drugs has partially surpassed this issue. However, in the setting of concomitant atrial fibrillation (AF) and PCI clopid...
Autores principales: | Berteotti, M., Gori, A. M., Giusti, B., Fortini, A., Grossi, G., Ciardetti, N., Migliorini, A., Lotti, E., Valenti, R., Di Mario, C., Marchionni, N., Marcucci, R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10147742/ https://www.ncbi.nlm.nih.gov/pubmed/36905562 http://dx.doi.org/10.1007/s11239-023-02784-z |
Ejemplares similares
-
Outcomes of Left Main Revascularization after Percutaneous Intervention or Bypass Surgery
por: Scudiero, Fernando, et al.
Publicado: (2022) -
Clinical Implications of “Tailored” Antiplatelet Therapy in Patients With Chronic Total Occlusion
por: De Gregorio, Maria Grazia, et al.
Publicado: (2020) -
Optimal antithrombotic treatment of patients with atrial fibrillation undergoing percutaneous coronary intervention: triple therapy is too much!
por: Jacobs, M. S., et al.
Publicado: (2018) -
The sunset of triple antithrombotic therapy for atrial fibrillation patients
por: Capranzano, Piera
Publicado: (2019) -
Impact of Platelet Reactivity in ACS Patients on Clinical Outcomes with Triple Antithrombotic Therapy
por: Gruttemeier, Julia, et al.
Publicado: (2021)